| abstract |
A combination comprising an atypical retinoid compound, preferably E-4- (3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid and an anticancer drug of the platinum family, preferably cisplatin, together witha pharmaceutical composition comprising it and a kit for its administration in unitary or in coordinated sequential form.The kit preferably comprises a first formulation of E-4-(3-(1-adamantyl)-4-hydroxyphenyl)cinnamic acid dissolved in a mixture of ethanol and cremophor, and suspended in a saline solution, and a second formulation of cisplatin in saline solution.The combination is used for the preparation of a medicament to inhibit tumor growth and tumor migration,in particular for the treatment of ovarian tumor and/or carcinoma. |